MARKET

AVTX

AVTX

Avalo Therapeutics Inc
NASDAQ
14.50
+0.30
+2.11%
Opening 09:53 04/25 EDT
OPEN
13.95
PREV CLOSE
14.20
HIGH
14.50
LOW
13.65
VOLUME
7.26K
TURNOVER
0
52 WEEK HIGH
1,130.40
52 WEEK LOW
3.950
MARKET CAP
14.99M
P/E (TTM)
-0.1277
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at AVTX last week (0415-0419)?
Weekly Report · 3d ago
Avalo Therapeutics (AVTX) Price Target Increased by 4566.67% to 35.70
NASDAQ · 04/17 01:38
Oppenheimer Upgrades Avalo Therapeutics (AVTX)
NASDAQ · 04/17 01:38
Avalo Therapeutics' Newly Acquired Ex-Eli Lilly Drug Could Stand Out In Competitive Hidradenitis Suppurativa Market, Analyst Upgrades
Oppenheimer upgraded Avalo Therapeutics Inc (NASDAQ:AVTX) to Outperform. The analyst says AVTX-009 is a promising drug candidate and looks forward to a Phase 2 topline data in 2026 in hidradenitis suppurativa. In March, Avalo announced the acquisition of an anti-IL-1β drug candidate.
Benzinga · 04/16 18:25
Avalo Therapeutics Price Target Announced at $35.00/Share by Oppenheimer
Dow Jones · 04/16 13:03
Avalo Therapeutics Raised to Outperform From Perform by Oppenheimer
Dow Jones · 04/16 13:03
AVALO THERAPEUTICS <AVTX.O>: OPPENHEIMER RAISES TO OUTPERFORM FROM PERFORM
Reuters · 04/16 12:53
Oppenheimer Upgrades Avalo Therapeutics to Outperform, Announces $35 Price Target
Benzinga · 04/16 12:52
More
About AVTX
Avalo Therapeutics, Inc. is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The Company's lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases. Its pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein). AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity. IL- 1β is a central driver in the inflammatory process. Quisovalimab is a fully human monoclonal antibody (mAb), directed against human LIGHT (Lymphotoxin-like, exhibits Inducible expression, and competes with Herpes Virus Glycoprotein D for Herpesvirus Entry Mediator (HVEM), a receptor expressed by T lymphocytes). AVTX-008 is a fully human B and T Lymphocyte Attenuator (BTLA) agonist fusion protein. AVTX-008 is differentiated by having specific binding to BTLA, with no binding to LIGHT or CD160.

Webull offers Avalo Therapeutics Inc stock information, including NASDAQ: AVTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AVTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AVTX stock methods without spending real money on the virtual paper trading platform.